← Therapy pipeline
Investigational · Obesity development

VCT220 / CX11

VCT220 · CX11 · oral small-molecule GLP-1 receptor agonist · CORXEL / Vincentage Pharma

The same oral small-molecule GLP-1 medicine is called VCT220 in China and CX11 outside Greater China; obesity studies are at different stages by region.

GLP-1
Obesity stagePhase 3Updated as of November 2026
SponsorCORXEL / Vincentage Pharma
TargetsGLP-1
RouteOral tablet
DevelopmentFormulations differ
01 / Evidence

Selected study results

VCT220 · China Phase 3 · 120 mgMean body-weight reductionBody weight decreased 12.2% · 52 weeks · Phase 3
Phase 3 · Oral · Sponsor-reported numerical results

Mean body-weight reduction · 52 weeks

Study focus: Weight management

A separate 160 mg group had 12.4% mean weight reduction; both China Phase 3 dose groups are reported below.

Investigational regimen
12.2%
Placebo / comparator
1.3%

Adults with obesity or overweight and a weight-related comorbidity in China · 120 mg once daily vs placebo · Trial N=840 · Sponsor topline. Results & methods ↗

Additional results or analyses from this same study
  • Same China Phase 3 study · 160 mg groupThe separate 160 mg group had 12.4% mean body-weight reduction versus 1.3% with placebo at 52 weeks. It is a dose arm within the same trial, not a separate study.

Sponsor topline from a China trial; results are not head-to-head with the separate U.S. Phase 2 study.

CX11 · U.S. Phase 2Maximum reported mean body-weight reduction across four regimensBody weight decreased 11.5% · 36-week follow-up; primary endpoint at week 26 · Phase 2
Phase 2 · Oral · Sponsor-reported numerical results

Maximum reported mean body-weight reduction across four regimens · 36-week follow-up; primary endpoint at week 26

Study focus: Weight management

Sponsor-reported full results from a randomized, double-blind, placebo-controlled U.S. trial.

CX11 · maximum reported regimen mean
11.5%
Placebo
3.1%

Adults with obesity or overweight in the United States · 120 mg, 160 mg, or 200 mg with fast or slow titration, once daily · Trial N=246 · Per-protocol set; least-squares means; hypothetical handling of intercurrent events. Results & methods ↗

CX11 · U.S. Phase 2 · regimen ranges, not dose-mapped values
TimepointCX11 mean weight reductionPlacebo
Week 26 · primary endpoint8.0–9.0%2.8%
Week 36 · follow-up9.3–11.5%3.1%
Additional results or analyses from this same study
  • U.S. Phase 2 · safetyDiscontinuation for gastrointestinal treatment-emergent adverse events was 5.0% across the combined CX11 groups versus 2.2% with placebo. Gastrointestinal events occurred mainly during dose escalation and were mild to moderate.

The 11.5% chart value is the maximum across four regimens, not a pooled mean. The release reports ranges without mapping each mean weight change to a dose. This U.S. Phase 2 trial is separate from China VCT220; global Phase 3 remains planned.

Each graphic shows results within one study. Alternate analyses and follow-up from that study are labeled together. Study averages are not individual predictions or cross-trial comparisons.

02 / How it works

Mechanism at a glance

GLP-1GLP-1Targeted
GIPGIP—
GCGglucagon—
AMYamylin—
OTHOther targets—
Explore the hormone anatomy ↗
03 / Development

Obesity stage by formulation

VCT220 · ChinaOral tablet
Phase 3China Phase 3 topline reported; NDA planned near term
CX11 · U.S./globalOral tablet
Phase 2U.S. Phase 2 topline reported; global Phase 3 planned, not initiated
Milestone → next

Latest: China Phase 3 VCT220 topline and U.S. Phase 2 CX11 topline were reported. CORXEL says that following an End-of-Phase-2 meeting it aligned with the FDA on key elements of CX11’s Phase 3 design and regulatory path; global Phase 3 is planned and in preparation.

Next: Global Phase 3 initiation and design; China NDA submission.

04 / Study records

Clinical study records

Obesity and weight-management studies appear first. Related-condition trials follow by phase, with focus labels to show what each study evaluates. Study stage and results reporting are listed separately. Results summarized above are identified as peer-reviewed or sponsor reported. Otherwise, the label states whether results were posted to a registry or reported in the linked source.

Obesity and weight-management studies

Phase 3 studies1 record

Phase 3

VCT220 China obesity Phase 3

Weight management
Study: CompletedResults: No registry results posted yetStatus reviewed November 2026

NCT06939296; 840 participants; 52-week Phase 3 study in China.

Phase 2 studies1 record

Phase 2

CX11 U.S. obesity Phase 2

Weight management
Study: CompletedResults: Sponsor results shown aboveStatus reviewed November 2026

246 adults in a 36-week U.S. placebo-controlled study. Primary weight endpoint at week 26; week-36 follow-up and pooled safety are reported separately. Global Phase 3 is planned, not initiated.